WILMINGTON, DE — Exicure Inc. (Nasdaq: XCUR) has agreed to sell its GPC-100 cancer drug development assets to South Korea-based GPCRT Inc. for approximately $4.8 million, a transaction intended to strengthen the Wilmington biotechnology company’s finances as it evaluates strategic alternatives.
The agreement, signed November 4, 2026, covers the GPC-100 program, also known as burixafor, which is being studied in combination with propranolol to mobilize stem cells in patients with multiple myeloma.
Exicure’s wholly owned subsidiary, GPCR Therapeutics USA Inc., completed a Phase 2 clinical trial of the treatment in January 2026.
Under the agreement, GPCRT will pay 6.5 billion South Korean won, equivalent to approximately $4.8 million, for the program’s intellectual property, licensing rights, clinical and regulatory data, contracts, materials and equipment.
The purchase price includes 500 million won previously paid by GPCRT, which will be credited toward the transaction. An additional 2 billion won was scheduled for payment by November 16, with the remaining 4 billion won due at closing, unless the parties agree to different payment dates.
The transaction would transfer Exicure’s rights under a January 19, 2025, license and collaboration agreement with GPCR Therapeutics Inc., along with the associated development assets.
GPCRT would assume future obligations under that agreement, including milestone and royalty payments, as well as responsibilities under the assigned program contracts.
The buyer would also bear GPC-100 program costs incurred beginning September 1, 2026, under the terms of the transaction.
Exicure and GPCR Therapeutics USA would retain other liabilities, including those associated with the program before September 1.
The arrangement would shift future development expenses and contractual obligations associated with GPC-100 to GPCRT while providing Exicure with cash proceeds from the sale.
GPCR Therapeutics USA will remain a wholly owned subsidiary of Exicure after the transaction closes.
GPC-100 is an investigational treatment being evaluated for stem cell mobilization in multiple myeloma, a cancer affecting plasma cells in the bone marrow.
Stem cell mobilization is used to move blood-forming stem cells from the bone marrow into the bloodstream, where they can be collected for transplantation procedures.
The proposed sale follows completion of the program’s Phase 2 trial earlier this year and forms part of Exicure’s continuing review of strategic options aimed at maximizing shareholder value.
Completion remains subject to customary closing conditions, including required regulatory or other approvals, third-party consents and a waiver and release from GPCR Therapeutics Inc.
Shareholder approval may also be required.
Exicure cautioned that the transaction is not guaranteed to close on the anticipated timetable or at all.
The company disclosed additional terms of the agreement in a Form 8-K filing with the U.S. Securities and Exchange Commission.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
